While the integrin–FAK signaling axis and Myc oncogenic network are both implicated in promoting HGSOC tumor development and progression,17, 30, 34 a simultaneous targeting of these two key drivers has rarely been considered as a targeted therapy for the treatment of such deadly disease. This evidence concerns the gene MYC and neoplasm.